# US 2017/0291937 A1 · Methods for Treating Hyperlipidemia with an ANGPTL8 Inhibitor and an ANGPTL3 Inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0291937 A1
- Document ID: US20170291937A1
- Status: Published application
- Kind: A1
- Application number: 15/482,499
- Filed: 2017-04-07
- Published: 2017-10-12
- Earliest claimed: 2016-04-08
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Jesper Gromada; Viktoria Gusarova; Andrew J. Murphy
- Web page: https://patentgrep.com/patent/US20170291937A1

## CPC

- C07K 16/22: against growth factors {; against growth regulators}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/00: Drugs for disorders of the endocrine system
- A61P 13/12: of the kidneys
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods for treating patients suffering from hyperlipidaemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to angiopoietin-like protein 8 (ANGPTL8) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3). The combination of an anti-ANGPTL8 antibody with an anti-ANGPTL3 antibody is useful in treating diseases such as hypercholesterolemia, including familial hypercholesterolemia (FH), both heFH and hoFH, as well as hyperlipidaemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

## Claims

### Claim 1

A method of treating a patient suffering from hyperlipidaemia, the method comprising administering to the patient a therapeutically effective amount of a combination of an angiopoietin-like protein 8 (ANGPTL8) inhibitor and an inhibitor of angiopoietin-like protein 3 (ANGPTL3).

### Claim 2 (depends on 1)

The method of claim 1, wherein the hyperlipidaemia is familial hyperlipidaemia or acquired hyperlipidaemia.

### Claim 3 (depends on 1)

The method of claim 1, wherein the hyperlipidaemia is selected from the group consisting of hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, and hyper chylomicronemia.

### Claim 4 (depends on 2)

The method of claim 2, wherein the familial hyperlipidaemia is hypercholesterolemia selected from the group consisting of heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH).

### Claim 5 (depends on 2)

The method of claim 2, wherein the acquired hyperlipidaemia is the result of excessive drinking of alcohol, obesity, side effects of medications (e.g. hormones or steroids), diabetes, kidney disease, underactive thyroid gland, or pregnancy.

### Claim 6 (depends on 1)

The method of claim 1, wherein the ANGPTL8 inhibitor is an antibody, or an antigen-binding fragment thereof, that binds specifically to ANGPTL8.

### Claim 7 (depends on 6)

The method of claim 6, wherein the antibody, or antigen-binding fragment thereof, that binds specifically to ANGPTL8 comprises the complementary determining regions (CDRs) of a heavy chain variable (HCVR) having the amino acid sequence of SEQ ID NO: 1 and the CDRs of a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 5.

### Claim 8 (depends on 6)

The method of claim 6, wherein the antibody, or antigen-binding fragment thereof, that binds specifically to ANGPTL8 comprises a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 2, a HCDR2 having the amino acid sequence of SEQ ID NO: 3, a HCDR3 having the amino acid sequence of SEQ ID NO: 4, a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 6, a LCDR2 having the amino acid sequence of SEQ ID NO: 7, and a LCDR3 having the amino acid sequence of SEQ ID NO: 8.

### Claim 9 (depends on 6)

The method of claim 6, wherein the antibody, or antigen-binding fragment thereof, that binds specifically to ANGPTL8 comprises a HCVR having the amino acid sequence of SEQ ID NO: 1 and a LCVR having the amino acid sequence of SEQ ID NO: 5.

### Claim 10 (depends on 1)

The method of claim 1, wherein the ANGPTL8 inhibitor is administered to the patient subcutaneously or intravenously.

### Claim 11 (depends on 1)

The method of claim 1, wherein the ANGPTL3 inhibitor is an antibody, or an antigen-binding fragment thereof, that binds specifically to ANGPTL3.

### Claim 12 (depends on 11)

The method of claim 11, wherein the ANGPTL3 antibody is evinacumab.

### Claim 13 (depends on 11)

The method of claim 11, wherein the antibody, or antigen-binding fragment thereof, that binds specifically to ANGPTL3 comprises the complementary determining regions (CDRs) of a heavy chain variable (HCVR) having the amino acid sequence of SEQ ID NO: 10 and the CDRs of a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 14.

### Claim 14 (depends on 11)

The method of claim 11, wherein the antibody, or antigen-binding fragment thereof, that binds specifically to ANGPTL3 comprises a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 11, a HCDR2 having the amino acid sequence of SEQ ID NO: 12, a HCDR3 having the amino acid sequence of SEQ ID NO: 13, a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 15, a LCDR2 having the amino acid sequence of SEQ ID NO: 16, and a LCDR3 having the amino acid sequence of SEQ ID NO: 17.

### Claim 15 (depends on 11)

The method of claim 11, wherein the antibody, or antigen-binding fragment thereof, that binds specifically to ANGPTL3 comprises a HCVR having the amino acid sequence of SEQ ID NO: 10 and a LCVR having the amino acid sequence of SEQ ID NO: 14.

### Claim 16 (depends on 11)

The method of claim 11, wherein the ANGPTL3 antibody, or antigen-binding fragment thereof, is administered to the patient subcutaneously or intravenously.

### Claim 17

A method of reducing the level of at least one lipid parameter in a patient suffering from a disorder or condition characterized in part by elevated levels of lipids or lipoproteins, the method comprising administering to the patient a therapeutically effective amount of a combination of an angiopoietin-like protein 8 (ANGPTL8) inhibitor and an inhibitor of angiopoietin-like protein 3 (ANGPTL3).

### Claim 18 (depends on 17)

The method of claim 17, wherein the disorder or condition is hyperlipidaemia selected from the group consisting of familial hyperlipidaemia and acquired hyperlipidaemia.

### Claim 19 (depends on 17)

The method of claim 17, wherein the disorder or condition is hyperlipidaemia selected from the group consisting of hyperlipoproteinemia, hypercholesterolemia, hypertriglyceridemia, and hyper chylomicronemia.

### Claim 20 (depends on 18)

The method of claim 18, wherein the familial hyperlipidaemia is hypercholesterolemia selected from the group consisting of heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH).

### Claim 21 (depends on 18)

The method of claim 18, wherein the acquired hyperlipidaemia is the result of excessive drinking of alcohol, obesity, side effects of medications (e.g. hormones or steroids), diabetes, kidney disease, underactive thyroid gland, or pregnancy.

### Claim 22 (depends on 17)

The method of claim 17, wherein the ANGPTL8 inhibitor is an antibody, or an antigen-binding fragment thereof, that binds specifically to ANGPTL8.

### Claim 23 (depends on 22)

The method of claim 22, wherein the antibody, or antigen-binding fragment thereof, that binds specifically to ANGPTL8 comprises the complementary determining regions (CDRs) of a heavy chain variable (HCVR) having the amino acid sequence of SEQ ID NO: 1 and the CDRs of a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 5.

### Claim 24 (depends on 22)

The method of claim 22, wherein the antibody, or antigen-binding fragment thereof, that binds specifically to ANGPTL8 comprises a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 2, a HCDR2 having the amino acid sequence of SEQ ID NO: 3, a HCDR3 having the amino acid sequence of SEQ ID NO: 4, a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 6, a LCDR2 having the amino acid sequence of SEQ ID NO: 7, and a LCDR3 having the amino acid sequence of SEQ ID NO: 8.

### Claim 25 (depends on 22)

The method of claim 22, wherein the antibody, or antigen-binding fragment thereof, that binds specifically to ANGPTL8 comprises a HCVR having the amino acid sequence of SEQ ID NO: 1 and a LCVR having the amino acid sequence of SEQ ID NO: 5.

### Claim 26 (depends on 22)

The method of claim 22, wherein the ANGPTL8 antibody, or antigen-binding fragment thereof, is administered to the patient subcutaneously or intravenously.

### Claim 27 (depends on 17)

The method of claim 17, wherein the ANGPTL3 inhibitor is an antibody, or an antigen-binding fragment thereof, that binds specifically to ANGPTL3.

### Claim 28 (depends on 27)

The method of claim 27, wherein the ANGPTL3 antibody is evinacumab.

### Claim 29 (depends on 27)

The method of claim 27, wherein the antibody, or antigen-binding fragment thereof, that binds specifically to ANGPTL3 comprises the complementary determining regions (CDRs) of a heavy chain variable (HCVR) having the amino acid sequence of SEQ ID NO: 10 and the CDRs of a light chain variable region (LCVR) having the amino acid sequence of SEQ ID NO: 14.

### Claim 30 (depends on 27)

The method of claim 27, wherein the antibody, or antigen-binding fragment thereof, that binds specifically to ANGPTL3 comprises a heavy chain CDR1 (HCDR1) having the amino acid sequence of SEQ ID NO: 11, a HCDR2 having the amino acid sequence of SEQ ID NO: 12, a HCDR3 having the amino acid sequence of SEQ ID NO: 13, a light chain CDR1 (LCDR1) having the amino acid sequence of SEQ ID NO: 15, a LCDR2 having the amino acid sequence of SEQ ID NO: 16, and a LCDR3 having the amino acid sequence of SEQ ID NO: 17.

### Claim 31 (depends on 27)

The method of claim 27, wherein the antibody, or antigen-binding fragment thereof, that binds specifically to ANGPTL3 comprises a HCVR having the amino acid sequence of SEQ ID NO: 10 and a LCVR having the amino acid sequence of SEQ ID NO: 14.

### Claim 32 (depends on 27)

The method of claim 27, wherein the ANGPTL3 antibody, or antigen-binding fragment thereof, is administered to the patient subcutaneously or intravenously.

### Claim 33 (depends on 1)

The method of claim 1, wherein the ANGPTL8 inhibitor and the ANGPTL3 inhibitor are administered concurrently or sequentially.

### Claim 34 (depends on 1)

The method of claim 1, wherein the ANGPTL8 inhibitor and the ANGPTL3 inhibitor are administered at therapeutically effective concentrations in separate pharmaceutical compositions or are co-formulated in one pharmaceutical composition.
